You are here
Acumen Pharmaceuticals, Inc
UEI: YHM4FW9X3YC3
# of Employees: 4
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.
Amount: $222,192.00In the United States in an estimated million people suffered from Alzheimer s disease AD with as many as being undiagnosed Alzheimer s Association Three stages of AD are propos ...
STTRPhase I2016Department of Health and Human Services National Institutes of Health -
Development and validation of a sensitive and selective assay for quantitating so
Amount: $176,145.00DESCRIPTION (provided by applicant): In the United States in 2013, 5.2 million people are estimated to suffer from Alzheimer's disease, with as many as 50% being undiagnosed [Alzheimer's Ass ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Drug discovery of anti-ADDL therapeutics for Alzheimer's
Amount: $183,750.00DESCRIPTION (provided by applicant): Recent evidence suggests that the primary cause of Alzheimer's disease is the progressive accumulation of neurotpxic oligomeric assemblies of the Abeta 1-42 prote ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
Biomarker for Alzheimer's Related Cognitive Deficits
Amount: $145,774.00DESCRIPTION (provided by applicant): The molecular and cellular details underlying Alzheimer's disease (AD) are being defined at an accelerating pace, leading to new therapeutic discovery efforts tha ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health
